ESMO 2023

5 year follow-up

Highlights in eBC

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Preoperative checkpointinihition in ER+ disease

DATO-DX - where is it going?

My highlights of ESMO23 in metastatic breast cancer

The FGFR story in bladder cancer at ESMO23

Clearing up non-clear cell RCC

Lu-PSMA leads forward

New 3rd line therapy for RCC

Early use of enzalutamide in advanced prostate cancer

When the history of ADC is written: Redefining first-line standard of care in mUC!

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

ALINA - immediate change of practice!

My highlights from ESMO 2023

Tarlatamab in SCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

New and better biomarkers are needed!

Anticipated updates and exciting new data for checkpointinhibitors

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

What is your definition of triple-negative breast cancer?

What was the most exciting news at ESMO23?

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

My highlights of ESMO23 in early breast cancer

ER-low corresponds diagnostically to ER-0 breast cancer

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Consolidation of data in early HR+ and triple-negative breast cancer

New data on neoadjuvant immunotherapy

HR+ study with > 20 % PCR

Analysis of tumour microenvironment and immunophenotype in TNBC

Preoperative checkpointinihition in ER+ disease

Immunoncology in eBC - triple negative and more?

Highlights in eBC

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Pembrolizumab solidifies as SOC in early-stage TNBC

Clinically relevant effect of pembro also in PCR

Detailed view of nodal-negative patients

Carry-over effects in monarchE confirmed

5 year follow-up

Ribociclib effective in all subtypes

Negative EFS results from NeoTrip

Our guidelines are correct

MonarchE - trial update

Neoadjuvant IO - is their new strategy in HR+ breast cancer

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

Studio NeoTrip: negativi i risultati

Punti salienti in eBC

MonarchE - mise à jour de l'essai

Nouvelles données sur l'immunothérapie néoadjuvante

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

New targets, new linker, new ADCs - much more to learn with new therapies!

How to organize a molecular tumorboards in breast cancer?

Improvement of therapy outcome by app-based patient education

New ADC for metastatic breast cancer?

What was the most exciting news at ESMO23?

New ADC in HR+ disease

Duvalumab + Dato-DXd effective

TULIP: Trastuzumab duocarmazine without OS benefit

Patient-centered molecular medicine - a new approach

T-DXd - new standard of care for brain mets?

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

T-DXd also effective for brain metastases

Our guidelines are correct

Improved oncological therapy with the smartphone

Even more new generation ADCs in breast cancer?

DATO-DX - where is it going?

Still on track for success in HER2-low MBC

Benefit for SG even after intensive pretreatment

My highlights of ESMO23 in metastatic breast cancer

Can surgery be spared following primary systemic therapy?

ADC + Immunotherapy - the BEGONIA study paradigm

Abemaciclib remains consistent in 5-year follow-up

Robust data from the monarchE

OP seems to be dispensable for super responders

Fulvestran better than anastrozole, but no survival benefit

Dato-DXd - new player in advanced luminal disease

TROP2 expression as a potential mechanism of resistance in HER2+ patients

HS20089 - a novel ADC is coming for TNBC

HER2DX in the PHERgain trial

Highlights in mBC

T-DXd in HER2+ patients with brain metastases

Remarkable efficacies in patients with HER2+ mBC with brain metastases

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

Lo studio BEGONIA nelle paziento con tumore triplo negativo

Punti salienti in mBC

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

T-DXd - nowy standard postępowania w przerzutach do mózgu?

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

HER2DX en el estudio PHERgain

What is the future of immune therapy in prostate cancer?

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Should we use zoledronic acid in all ADT patients?

Targeted therapy will move forward - but more robust data is needed.

Negative data for pembrolizumab in mHSCPC & mCRPC

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

EMBARK expands ENZA indication to PCa

Salvage radiotherapy the new standard

PSMAfore unleashes urooncologic opportunity

CXCR2 inhibitor in PCa

Embark without fear

RADICALS RT: Trial and controversies

Osteoprotection at mHSPC

Longterm toxicity of adjuvant RT after prostatectomy

Precision medicine at mCRCP

IO therapy in metastatic prostate cancer.

Immunotherapy in metastatic PCa

Lu-PSMA leads forward

EMBARK - Quality of Life

Combination of radioligand therapy with chemotherapy useful

Early use of enzalutamide in advanced prostate cancer

Big data and AI prediction tools

TITAN: ultra-low PSA = best prognosis

Brave New World in mCRPC

PSMA FORE: Trial and controversies

ENZA P:Trial and controversies

STAMPEDE data. Skelettstärkande och riskstratifiering.

Big Data och AI för prediktion vid prostatacancer

EMBARK och livskvalitet

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

CXCR2 hämmare och prostatacancer

Immunterapi vid prostatacancer

Part1: New standard of care in first line urothelial cancer?!

Part 2: New standard of care in first line urothelial cancer!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

DAD, DAD-IO

FGFR inhibitors: What is the best scenario for this family of compounds?

EV + Pembro as standard of care in first-line therapy of bladder cancer

The FGFR story in bladder cancer at ESMO23

When the history of ADC is written: Redefining first-line standard of care in mUC!

Chemo-IO establishes itself in the first-line treatment of bladder cancer

New SoC in firstline bladder cancer

Amazing new data in bladder cancer

Unique bladder delivery system of gemcitabine herolds remarkable response

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Is de-escalating therapy ready for prime-time?

Important new treatment option but only for subset of patients?

Where does the future therapy go in renal cell carcinoma?

Kidney cancer highlights at ESMO23

New 3rd line therapy for RCC

Belzutifan - whats next kidney cancer?

Intermittent therapy also possible with TKIs

Belzutifan in later lines of therapy

New mode of action in mRCC - ready for prime time?

Clearing up non-clear cell RCC

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

My highlights from ESMO 2023

Substantial improvement in local regional NSCLC

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Perioperative IO: OS-benefi from KEYNOTE-671

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Circulating DNA in AEGEAN trial

Big improvements in early stage and a subset of metatstic NSCLC

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Scene is set for inductive immunotherapy

ALINA - immediate change of practice!

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

Activating EGFR-mutation - what's coming up?

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Evolving landscape of ADCs

ESMO2023-impact on everyday practice!

Amivantamab upfront? MARIPOSA trial

Treatment sequences for EGFR-mutated Patients

My highlights from ESMO 2023

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Substantial improvement in rare alterations

Amivantamab at progression? MARIPOSA-2 trial

MARIPOSA II: Trial and controversies

By unanimous decision and still the champion – docetaxel!

Changing treatment landscape in EGFR-mutated NSCLC

NRG fusions: a new drugable target?

Brain metastases – options to improve the systemic treatment

Does immunotherapy still have a place in EGFR-positive mNSCLC?

LIBRETO - a positive study, but was it necessary?

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Big improvements in early stage and a subset of metatstic NSCLC

Do ADCs have brain activity?

MARIPOSA: Trial and controversies

PAPILLON - bringing together therapy for the 1st line

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

TROPION-Lung01: positive development

Practice changing results on exon 20 insertion mNSCLC

Quelles séquences thérapeutiques pour les patients EGFR mutés

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Les points forts de l'ESMO 2023

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Amivantamab at progression? MARIPOSA-2 trial

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Amivantamab upfront? MARIPOSA trial

I miei punti salienti di ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

Impact of T-cell engagers in SCLC

A new option in relapsed SCLC

New hope for patients with SCLC

Tarlatamab in SCLC

Neue Hoffnung für Patienten mit SCLC

Evolution of the revolution - the RUBY trial

New data on H&N Cancer

First data on luveltamab in multiline treatment for endometrial cancer

New data on sarkomas

Update on gynaecological cancers

PCO Therapeutics

Precision oncology in CUP